Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2015 | Pages:
247 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Psoriatic Arthritis - Pipeline Review, H2 2015 Summary Global Markets Direct's, 'Psoriatic Arthritis - Pipeline Review, H2 2015', provides an overview of the Psoriatic Arthritis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Psoriatic Arthritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Psoriatic Arthritis and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Psoriatic Arthritis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Psoriatic Arthritis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Psoriatic Arthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Psoriatic Arthritis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons To Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Psoriatic Arthritis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Psoriatic Arthritis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Psoriatic Arthritis Overview 9 Therapeutics Development 10 Pipeline Products for Psoriatic Arthritis - Overview 10 Pipeline Products for Psoriatic Arthritis - Comparative Analysis 11 Psoriatic Arthritis - Therapeutics under Development by Companies 12 Psoriatic Arthritis - Therapeutics under Investigation by Universities/Institutes 16 Psoriatic Arthritis - Pipeline Products Glance 17 Late Stage Products 17 Clinical Stage Products 18 Early Stage Products 19 Unknown Stage Products 20 Psoriatic Arthritis - Products under Development by Companies 21 Psoriatic Arthritis - Products under Investigation by Universities/Institutes 23 Psoriatic Arthritis - Companies Involved in Therapeutics Development 24 AbbVie Inc. 24 AbGenomics International, Inc. 25 Alder Biopharmaceuticals Inc. 26 Amgen Inc. 27 AstraZeneca Plc 28 Avesthagen Limited 29 Berg LLC 30 BIOCAD 31 Biocon Limited 32 Bionovis SA 33 Boehringer Ingelheim GmbH 34 Bristol-Myers Squibb Company 35 Celgene Corporation 36 Celltrion, Inc. 37 Coherus BioSciences, Inc. 38 Eli Lilly and Company 39 Epirus Biopharmaceuticals, Inc. 40 Forward Pharma A/S 41 Genor BioPharma Co., Ltd. 42 Hetero Drugs Limited 43 Inbiopro Solutions Pvt. Ltd. 44 Innovent Biologics, Inc. 45 Johnson & Johnson 46 Kineta, Inc. 47 Mabion SA 48 Mabtech Limited 49 Momenta Pharmaceuticals, Inc. 50 Mycenax Biotech Inc. 51 Novartis AG 52 Novo Nordisk A/S 53 Oncobiologics, Inc. 54 Panacea Biotec Limited 55 Pfizer Inc. 56 Sandoz International GmbH 57 Swedish Orphan Biovitrum AB 58 Therapeutic Proteins International, LLC 59 UCB S.A. 60 Vitae Pharmaceuticals, Inc. 61 Xbrane Bioscience AB 62 Psoriatic Arthritis - Therapeutics Assessment 63 Assessment by Monotherapy Products 63 Assessment by Target 64 Assessment by Mechanism of Action 67 Assessment by Route of Administration 70 Assessment by Molecule Type 72 Drug Profiles 74 abatacept - Drug Profile 74 AbGn-168H - Drug Profile 77 ABT-122 - Drug Profile 78 adalimumab biosimilar - Drug Profile 80 adalimumab biosimilar - Drug Profile 81 adalimumab biosimilar - Drug Profile 82 adalimumab biosimilar - Drug Profile 83 adalimumab biosimilar - Drug Profile 84 adalimumab biosimilar - Drug Profile 85 adalimumab biosimilar - Drug Profile 86 adalimumab biosimilar - Drug Profile 87 adalimumab biosimilar - Drug Profile 88 adalimumab biosimilar - Drug Profile 89 adalimumab biosimilar - Drug Profile 90 adalimumab biosimilar - Drug Profile 91 adalimumab biosimilar - Drug Profile 92 adalimumab biosimilar - Drug Profile 93 adalimumab biosimilar - Drug Profile 94 anakinra (recombinant) - Drug Profile 95 apremilast - Drug Profile 97 BI-655066 - Drug Profile 100 bimekizumab - Drug Profile 101 brodalumab - Drug Profile 102 certolizumab pegol biosimilar - Drug Profile 104 clazakizumab - Drug Profile 105 COVA-322 - Drug Profile 107 dalazatide - Drug Profile 108 dimethyl fumarate - Drug Profile 110 DNX-114 - Drug Profile 111 etanercept biosimilar - Drug Profile 112 etanercept biosimilar - Drug Profile 113 etanercept biosimilar - Drug Profile 114 etanercept biosimilar - Drug Profile 115 etanercept biosimilar - Drug Profile 116 etanercept biosimilar - Drug Profile 117 etanercept biosimilar - Drug Profile 118 etanercept biosimilar - Drug Profile 119 golimumab - Drug Profile 120 golimumab biosimilar - Drug Profile 123 golimumab biosimilar - Drug Profile 124 golimumab biosimilar - Drug Profile 125 guselkumab - Drug Profile 126 IBI-303 - Drug Profile 129 IBPM-004AM - Drug Profile 130 IBPM-005IX - Drug Profile 131 infliximab biobetter - Drug Profile 132 infliximab biosimilar - Drug Profile 133 infliximab biosimilar - Drug Profile 136 infliximab biosimilar - Drug Profile 138 infliximab biosimilar - Drug Profile 139 INV-17 - Drug Profile 140 itolizumab - Drug Profile 141 ixekizumab - Drug Profile 143 liraglutide (recombinant) - Drug Profile 144 Peptide to Inhibit CD44 for Rheumatoid and Psoriatic Arthritis - Drug Profile 147 secukinumab - Drug Profile 148 tofacitinib - Drug Profile 153 ubidecarenone - Drug Profile 157 ustekinumab biosimilar - Drug Profile 159 ustekinumab biosimilar - Drug Profile 160 VTP-43742 - Drug Profile 161 Psoriatic Arthritis - Recent Pipeline Updates 162 Psoriatic Arthritis - Dormant Projects 232 Psoriatic Arthritis - Discontinued Products 233 Psoriatic Arthritis - Product Development Milestones 234 Featured News & Press Releases 234 Appendix 242 Methodology 242 Coverage 242 Secondary Research 242 Primary Research 242 Expert Panel Validation 242 Contact Us 242 Disclaimer 243
List of Tables
Number of Products under Development for Psoriatic Arthritis, H2 2015 14 Number of Products under Development for Psoriatic Arthritis - Comparative Analysis, H2 2015 15 Number of Products under Development by Companies, H2 2015 17 Number of Products under Development by Companies, H2 2015 (Contd..1) 18 Number of Products under Development by Companies, H2 2015 (Contd..2) 19 Number of Products under Investigation by Universities/Institutes, H2 2015 20 Comparative Analysis by Late Stage Development, H2 2015 21 Comparative Analysis by Clinical Stage Development, H2 2015 22 Comparative Analysis by Early Stage Development, H2 2015 23 Comparative Analysis by Unknown Stage Development, H2 2015 24 Products under Development by Companies, H2 2015 25 Products under Development by Companies, H2 2015 (Contd..1) 26 Products under Investigation by Universities/Institutes, H2 2015 27 Psoriatic Arthritis - Pipeline by AbbVie Inc., H2 2015 28 Psoriatic Arthritis - Pipeline by AbGenomics International, Inc., H2 2015 29 Psoriatic Arthritis - Pipeline by Alder Biopharmaceuticals Inc., H2 2015 30 Psoriatic Arthritis - Pipeline by Amgen Inc., H2 2015 31 Psoriatic Arthritis - Pipeline by AstraZeneca Plc, H2 2015 32 Psoriatic Arthritis - Pipeline by Avesthagen Limited, H2 2015 33 Psoriatic Arthritis - Pipeline by Berg LLC, H2 2015 34 Psoriatic Arthritis - Pipeline by BIOCAD, H2 2015 35 Psoriatic Arthritis - Pipeline by Biocon Limited, H2 2015 36 Psoriatic Arthritis - Pipeline by Bionovis SA, H2 2015 37 Psoriatic Arthritis - Pipeline by Boehringer Ingelheim GmbH, H2 2015 38 Psoriatic Arthritis - Pipeline by Bristol-Myers Squibb Company, H2 2015 39 Psoriatic Arthritis - Pipeline by Celgene Corporation, H2 2015 40 Psoriatic Arthritis - Pipeline by Celltrion, Inc., H2 2015 41 Psoriatic Arthritis - Pipeline by Coherus BioSciences, Inc., H2 2015 42 Psoriatic Arthritis - Pipeline by Eli Lilly and Company, H2 2015 43 Psoriatic Arthritis - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2015 44 Psoriatic Arthritis - Pipeline by Forward Pharma A/S, H2 2015 45 Psoriatic Arthritis - Pipeline by Genor BioPharma Co., Ltd., H2 2015 46 Psoriatic Arthritis - Pipeline by Hetero Drugs Limited, H2 2015 47 Psoriatic Arthritis - Pipeline by Inbiopro Solutions Pvt. Ltd., H2 2015 48 Psoriatic Arthritis - Pipeline by Innovent Biologics, Inc., H2 2015 49 Psoriatic Arthritis - Pipeline by Johnson & Johnson, H2 2015 50 Psoriatic Arthritis - Pipeline by Kineta, Inc., H2 2015 51 Psoriatic Arthritis - Pipeline by Mabion SA, H2 2015 52 Psoriatic Arthritis - Pipeline by Mabtech Limited, H2 2015 53 Psoriatic Arthritis - Pipeline by Momenta Pharmaceuticals, Inc., H2 2015 54 Psoriatic Arthritis - Pipeline by Mycenax Biotech Inc., H2 2015 55 Psoriatic Arthritis - Pipeline by Novartis AG, H2 2015 56 Psoriatic Arthritis - Pipeline by Novo Nordisk A/S, H2 2015 57 Psoriatic Arthritis - Pipeline by Oncobiologics, Inc., H2 2015 58 Psoriatic Arthritis - Pipeline by Panacea Biotec Limited, H2 2015 59 Psoriatic Arthritis - Pipeline by Pfizer Inc., H2 2015 60 Psoriatic Arthritis - Pipeline by Sandoz International GmbH, H2 2015 61 Psoriatic Arthritis - Pipeline by Swedish Orphan Biovitrum AB, H2 2015 62 Psoriatic Arthritis - Pipeline by Therapeutic Proteins International, LLC, H2 2015 63 Psoriatic Arthritis - Pipeline by UCB S.A., H2 2015 64 Psoriatic Arthritis - Pipeline by Vitae Pharmaceuticals, Inc., H2 2015 65 Psoriatic Arthritis - Pipeline by Xbrane Bioscience AB, H2 2015 66 Assessment by Monotherapy Products, H2 2015 67 Number of Products by Stage and Target, H2 2015 69 Number of Products by Stage and Mechanism of Action, H2 2015 72 Number of Products by Stage and Route of Administration, H2 2015 75 Number of Products by Stage and Molecule Type, H2 2015 77 Psoriatic Arthritis Therapeutics - Recent Pipeline Updates, H2 2015 166 Psoriatic Arthritis - Dormant Projects, H2 2015 236 Psoriatic Arthritis - Discontinued Products, H2 2015 237
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
